Compilation of a Comprehensive Gene Panel for Systematic Assessment of Genes That Govern an Individual’s Drug Responses
October 2010
in “
Pharmacogenomics
”
Studysummary This study constructed a panel of pharmacokinetic and pharmacodynamic genes, revealing that current SNP chips insufficiently capture many drug-response gene variants, highlighting the need for complementary genetic approaches.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
In 2010, researchers compiled a comprehensive gene panel to assess individual drug responses, including 923 pharmacokinetic genes, 703 pharmacodynamic genes, and 720 miRNAs. They found that only 16.7% of these genes had SNPs with more than 80% coverage by commercial SNP chips, highlighting the chips' limitations in capturing rare SNPs and miRNA genes. The study concluded that the gene panel could be useful for evaluating genes and variants affecting drug responses and could complement genome-wide association studies (GWAS) by optimizing drug selection and dosing based on genetic factors. Despite the extensive gene selection, the study did not evaluate structural variations like copy number variations (CNVs), which may also affect drug responses.
